Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, State University of New York, Buffalo, New York 14214, USA.
J Pharmacol Exp Ther. 2013 Sep;346(3):504-13. doi: 10.1124/jpet.113.206250. Epub 2013 Jun 28.
γ-Hydroxybutyrate (GHB), a common drug of abuse, is often coingested with ethanol. Increasing renal clearance via monocarboxylate transporter (MCT) inhibition represents a potential therapeutic strategy in GHB overdose, as does inhibition of GABAB receptors. In this study, we investigate toxicokinetic/toxicodynamic interactions between GHB-ethanol and efficacy of treatment options for GHB-ethanol intoxication in rats. Sedation was assessed using the endpoint of return-to-righting reflex. Respiration was assessed using plethysmography. Coadministration of 2.0 g/kg ethanol i.v. with 600 mg/kg GHB i.v. increased sleep time compared with GHB alone. Administration of ethanol to steady-state concentrations of 0.1-0.2% and 0.3-0.4% (w/v) did not affect toxicokinetics of 600 mg/kg GHB i.v., or respiratory rate, but did result in significantly lower peak tidal volumes compared with GHB alone. Oral administration of 2.5 g/kg ethanol had no significant effect on toxicokinetics of 1500 mg/kg orally administered GHB. Pretreatment with specific receptor inhibitors indicated no effect of GABAA receptor inhibition on sleep time or respiratory depression in GHB-ethanol intoxication. GABAB receptor inhibition partially prevented sedation and completely prevented respiratory depression. Ethanol increased fatality when administered at 0.1-0.2% (4 of 10) and 0.3-0.4% (9 of 10) versus 1500 mg/kg GHB i.v. alone (0 of 10). Treatment with the MCT inhibitor, l-lactate, significantly decreased sleep time after GHB-ethanol and decreased fatality at 0.1-0.2% (0 of 10) and 0.3-0.4% ethanol (5 of 10). Treatment with a GABAB receptor antagonist completely prevented fatality at 0.3-0.4% (0 of 10). These data indicate that ethanol potentiates the sedative and respiratory depressant effects of GHB, increasing the risk of fatality. MCT and GABAB receptor inhibition represent potentially effective treatments in GHB-ethanol intoxication.
γ-羟基丁酸(GHB)是一种常见的滥用药物,常与乙醇同时摄入。通过单羧酸转运蛋白(MCT)抑制增加肾清除率是治疗 GHB 过量的一种潜在治疗策略,GABAB 受体抑制也是如此。在这项研究中,我们研究了 GHB-乙醇的毒代动力学/毒效动力学相互作用以及治疗 GHB-乙醇中毒的治疗选择在大鼠中的疗效。镇静作用通过恢复直立反射的终点来评估。通过 plethysmography 评估呼吸。静脉注射 2.0 g/kg 乙醇与静脉注射 600 mg/kg GHB 联合给药可增加睡眠时间与单独 GHB 相比。给予乙醇至 0.1-0.2%(w/v)和 0.3-0.4%(w/v)的稳定浓度不会影响 600 mg/kg GHB 的毒代动力学静脉注射,或呼吸频率,但与单独 GHB 相比,潮气量峰值明显降低。口服给予 2.5 g/kg 乙醇对口服给予 1500 mg/kg GHB 的毒代动力学无显著影响。特定受体抑制剂预处理表明 GABAA 受体抑制对 GHB-乙醇中毒中的睡眠时间或呼吸抑制无影响。GABAB 受体抑制部分预防镇静作用,并完全预防呼吸抑制。当给予 0.1-0.2%(10 只中的 4 只)和 0.3-0.4%(10 只中的 9 只)时,乙醇增加了死亡率与单独静脉注射 1500 mg/kg GHB(10 只中 0 只)相比。MCT 抑制剂 L-乳酸治疗可显著减少 GHB-乙醇后的睡眠时间,并降低 0.1-0.2%(10 只中的 0 只)和 0.3-0.4%乙醇(10 只中的 5 只)的死亡率。GABAB 受体拮抗剂治疗完全预防了 0.3-0.4%(10 只中的 0 只)的死亡率。这些数据表明,乙醇增强了 GHB 的镇静和呼吸抑制作用,增加了死亡风险。MCT 和 GABAB 受体抑制是 GHB-乙醇中毒的潜在有效治疗方法。